{"id":13364,"date":"2010-10-13T10:30:00","date_gmt":"2010-10-13T08:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/pfizer-compra-king\/"},"modified":"2010-10-13T10:30:00","modified_gmt":"2010-10-13T08:30:00","slug":"pfizer-compra-king","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/pfizer-compra-king\/","title":{"rendered":"Pfizer buys King"},"content":{"rendered":"<p>&nbsp;<\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 10pt\"><span style=\"mso-fareast-language: IT; mso-no-proof: yes\"><font size=\"3\"><font face=\"Calibri\">Pfizer has reached an agreement to buy drugmaker King Pharmaceuticals for $3.6 billion. The pharmaceutical group&#039;s goal is to boost revenues to cushion the impact of patent expirations on some of its main drugs. Pfizer will pay King Pharma $14.25 a share, equal to a premium of 40% on Monday&#039;s close.<\/p>\n<p><\/font><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 10pt\"><span style=\"mso-fareast-language: IT; mso-no-proof: yes\"><font face=\"Calibri\" size=\"3\"><em>Il sole 24 Ore \u2013 13 October 2010 \u2013 pag. 42<\/em><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 10pt\"><span style=\"mso-fareast-language: IT; mso-no-proof: yes\"><font face=\"Calibri\" size=\"3\"><\/font><\/span><\/p>\n<p>&nbsp;<\/p>\n<hr \/>\n<p>&nbsp;<\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 10pt\"><font size=\"2\"><span style=\"color: #505050; font-family: &quot;Verdana&quot;,&quot;sans-serif&quot;\">King Pharmaceuticals, founded in 1994, is a basic research pharmaceutical company that develops, manufactures, markets and sells prescription pharmaceuticals and animal health products. THE<font color=\"#000000\"> revenues grew from $ $13 million in 1994 to over $1.78 billion in 2009. King&#039;s workforce has grown from an initial 145 to more than 2,700 employees, of which 1,000 make up the outside operations force. It is based in Bristol, Tennessee<\/font><\/span><\/font><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 10pt\"><font size=\"2\"><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" id=\"il_fi\" height=\"170\" alt=\"\" width=\"148\" src=\"http:\/\/www.pharmalot.com\/wp-content\/uploads\/2008\/10\/brian-markison.jpg\" \/>&nbsp;<em><strong>Brian A. Markison <\/strong>Chairman, President and Chief Executive Officer. In 2008, he received a salary of $8.6 million.<\/em><\/p>\n<p><\/font><\/p>\n<p>&nbsp;<img loading=\"lazy\" decoding=\"async\" class=\"rg_hi\" id=\"rg_hi\" style=\"width: 189px; height: 267px\" height=\"267\" alt=\"\" width=\"189\" data-width=\"189\" data-height=\"267\" src=\"http:\/\/t3.gstatic.com\/images?q=tbn:ANd9GcSsJn4Lc_mnrw_HImbZdjAPUPyo12bNEIUIpYKYpbWNjgnqMkc&amp;t=1&amp;usg=__rDjSv5opwzK6ETUujaOGfORLcws=\" \/>&nbsp;<em>Jeff Kindler, CEO of Pfizer. In 2008 he received a salary of 14,788,302 $<\/em><\/p>\n<hr \/>","protected":false},"excerpt":{"rendered":"<p>&nbsp; Pfizer ha raggiunto un accordo per acquistare la casa farmaceutica King Pharmaceuticals per 3,6 miliardi di dollari. L&rsquo;obiettivo del gruppo farmaceutico &egrave; quello di potenziare i ricavi per attutire l&rsquo;impatto della scadenza dei brevetti su alcuni dei suoi principali farmaci. Pfizer pagher&agrave; per King Pharma 14,25 dollari ad azione, pari a un premio del &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13364","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13364"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13364\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}